KEI Comments Regarding NIH Exclusive License to Lyell Immunopharma for Cell Therapy Cancer Treatment

On June 8, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” (86 FR 27852). The inventions to be… Continue Reading

KEI Comments Concerning NIH Exclusive License to Kantum Pharma

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on June 8, 2021 regarding the “Prospective Grant of an Exclusive Patent License: P2Y14 Receptor Antagonists To Treat Kidney and Lung Inflammation” (86 FR 27858). The license… Continue Reading

KEI Comments to the NIH Regarding Prospective Exclusive License to UK firm Mevox

(Update: The NIH provided a response on June 23, 2021.) On June 2, 2021, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development, Commercialization, and Use… Continue Reading

WHA74: KEI’s statement on Public health emergencies: preparedness and response

At the World Health Organization’s 74th World Health Assembly, Knowledge Ecology International delivered the following remarks on “Public health emergencies: preparedness and response” on Monday, 31 May 2021. Non-state actors are limited to one minute statements. Knowledge Ecology International asks… Continue Reading

WHA74: KEI’s statement on the global strategy and plan of action on public health, innovation, and intellectual property

At the World Health Organization’s 74th World Health Assembly, Knowledge Ecology International delivered the following remarks on WHO’s global strategy and plan of action on public health, innovation, and intellectual property on Saturday, 29 May 2021. Non-state actors are limited… Continue Reading

21 May 2021: 62 WTO members submit revised proposal on a waiver from certain provisions of the TRIPS Agreement for the Prevention, Containment, and Treatment of COVID-19

On Friday, 21 May 2021, 62 WTO members (African Group, the Plurinational State of Bolivia, Egypt, Eswatini, Fiji, India, Indonesia, Kenya, the LDC Group, Maldives, Mozambique, Mongolia, Namibia, Pakistan, South Africa, Vanuatu, the Bolivarian Republic of Venezuela and Zimbabwe) submitted… Continue Reading

Texas A&M Vaccine Manufacturing Contract Shows that cGMP Manufacturing of COVID-19 Vaccines Can Start in Five Months 

A $265 million COVID-19 vaccine manufacturing contract between the Department of Health and Human Services (HHS) and the Texas A&M University System (TAMUS) to manufacture the Novavax and other COVID-19 vaccines demonstrates that a manufacturing facility can be retrofitted to… Continue Reading

KEI Comments on NIH Exclusive License to Australian firm SubRed

On Monday April 26, 2021, Knowledge Ecology International submitted comments regarding the “Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype” (86 FR 18545) by the… Continue Reading